Insight Molecular Diagnostics vs VolitionRx
IMDX and VNRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMDX and VNRX compare
Insight Molecular Diagnostics is the larger company, worth 23 times as much as VolitionRx ($58.2M against $2.6M).
VolitionRx grew revenue faster over the last twelve months (86.3% versus −60.8% for Insight Molecular Diagnostics).
VolitionRx keeps more of each dollar of sales as profit, with a net margin of −1043% compared with −2956% at Insight Molecular Diagnostics.
Insight Molecular Diagnostics scores higher on the StockData Score (7 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMDX | VNRX |
|---|---|---|
| Size and price | ||
| Market cap | $58.2M | $2.6M |
| Share price | $1.78 | $0.189 |
| Change, 1 year | −75.9% | −97.2% |
| Change, 5 years | −96.3% | −99.7% |
| Beta (5Y) | 2.66 | 2.26 |
| Employees | 58 | 75 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 34.9× | 1.0× (better) |
| FCF yield | −53.2% (better) | −760% |
| Growth | ||
| Revenue growth (TTM) | −60.8% | 86.3% (better) |
| Revenue growth, 5Y average | 27.2% | 164% (better) |
| Profitability | ||
| Gross margin | 48.3% | – |
| Operating margin | −3012% | −790% (better) |
| Net margin | −2956% | −1043% (better) |
| FCF margin | −1856% | −797% (better) |
| Financial health | ||
| Current ratio | 2.00 (better) | 0.30 |
| Altman Z-score | −24.27 (better) | −53.84 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −44.7% (better) | −751% |
| Shareholder yield | −44.7% (better) | −751% |
| Ownership | ||
| Held by institutions | 56.4% | 14.1% |
| Held by insiders | 81.6% | – |
| Insider net buying, 12 months | $5.7M (better) | $0 |
| Short interest, % of float | 17.0% | – |
Go deeper
- IMDX stock overview
- IMDX income statement
- IMDX valuation and score
- VNRX stock overview
- VNRX income statement
- VNRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.